Mirxes Holding Signs Strategic RNA Medicine Partnership with Walvax
I'm PortAI, I can summarize articles.
Mirxes Holding Co. Ltd. has signed an MOU with Walvax Biotechnology Co., Ltd. for a two-year strategic partnership. The collaboration aims to develop an RNA-centric preventive and precision medicine platform, focusing on joint development, clinical trials, registration, sales, and distribution of medical solutions. The goal is to advance early detection and preventive medicine. However, the collaboration under the MOU may or may not proceed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments